BioPharma Resources

Drug Trial Radar · NCT06152172

CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101

CARTIMMUNE: A Single-Center Study of Patients With Autoimmune Diseases Receiving an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (KYV 101)

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Aug 5, 2024

Primary completion

Feb 2027

Study completion Feb 2027

Sponsor

Lead sponsor
David PorterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Kyverna Therapeutics
First posted
Nov 30, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety, tolerability, and clinical activity of KYV 101 (a fully-human anti-CD19 CAR T-cell therapy) in adult subjects with B cell-driven autoimmune diseases. The trial anticipates enrolling participants to reach a maximum of 24 participants who will receive 1 dose of KYV-101 and will be followed for 2 years.

Conditions

  • Idiopathic Inflammatory Myopathies
  • Diffuse Cutaneous Systemic Sclerosis
  • SLE Nephritis
  • ANCA Associated Vasculitis

Interventions

  • KYV-101Drug

    The KYV-101 will be administered IV as a single infusion dosed at 1×108 CAR+ T cells.

  • CyclophosphamideDrug

    Lymphodepleting chemotherapy of cyclophosphamide (CYC) 300 mg/m2

  • FludarabineDrug

    Lymphodepleting chemotherapy of Fludarabine (FLU) 30 mg/m2 intravenously (IV)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of AEs in IIM.Time frame: 3 months after CAR infusion.
  2. Incidence and severity of AEs in IIM.Time frame: 6 months after CAR infusion.
  3. Incidence and severity of AEs in IIM.Time frame: 12 months after CAR infusion.
  4. Incidence and severity of AEs in IIM.Time frame: 24 months after CAR infusion.
  5. Incidence and severity of AEs in DCSSTime frame: 3 months after CAR infusion.
  6. Incidence and severity of AEs in DCSSTime frame: 6 months after CAR infusion.
  7. Incidence and severity of AEs in DCSSTime frame: 12 months after CAR infusion.
  8. Incidence and severity of AEs in DCSSTime frame: 24 months after CAR infusion.
  9. Incidence and severity of AEs in SLE NephritisTime frame: 3 months after CAR infusion.
  10. Incidence and severity of AEs in SLE NephritisTime frame: 6 months after CAR infusion.
  11. Incidence and severity of AEs in SLE NephritisTime frame: 12 months after CAR infusion.
  12. Incidence and severity of AEs in SLE NephritisTime frame: 24 months after CAR infusion.
  13. Incidence and severity of AEs in AAVTime frame: 3 months after CAR infusion.
  14. Incidence and severity of AEs in AAVTime frame: 6 months after CAR infusion.
  15. Incidence and severity of AEs in AAVTime frame: 12 months after CAR infusion.
  16. Incidence and severity of AEs in AAVTime frame: 24 months after CAR infusion.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital of the Universithy of Pennsylvania

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.